|
|||||
|
|
| 奥沙利铂联合5-FU／LV与伊利替康联合5-FU／LV比较治疗晚期结直肠癌的系统评价 | |
| 引用本文： | 王艇,罗黎力,周清华,吴泰相.奥沙利铂联合5-FU／LV与伊利替康联合5-FU／LV比较治疗晚期结直肠癌的系统评价[J].中国循证医学杂志,2008,8(1):36-41. |
| 作者姓名： | 王艇 罗黎力 周清华 吴泰相 |
| 作者单位： | 1. 四川大学华两医院肿瘤中心,成都,610041 2. 四川大学华两妇女儿童医院 3. 四川大学华西医院,天津医科大学总医院,天津市肺癌研究所 4. 四川大学华西医院中国循证医学中心临床流行病学教研室 |
| 摘 要： | 目的比较伊利替康联合5-FU／LV方案（IRI＋5-FU／LV）与奥沙利铂联合5-FU／LV方案（OXA＋5-FU／LV）治疗晚期结直肠癌的临床疗效和安全性。方法计算机检索Cochrane图书馆临床对照试验资料库（2007年第2期）、MEDLINE（1966～2007）、EMbase（1984～2004）、CBMdic（1978～2007）、CNKI（1994～2007）及相关会议论文集及药厂资料，纳入随机对照试验及半随机对照试验，采用Cochrane系统评价方法进行评价。结果共纳入7个研究2107例患者，OXA＋5-FU／LV方案显示出相对优于或等于IRI＋5-FU／LV方案的中位生存期和疾病进展时间，OXA＋5-FU／LV方案显示出相对较高的有效率和较低的毒副作用。结论晚期结直肠癌治疗中OXA＋5-Fu／LV方案比IRI＋5-FU／LV方案更适合患者。 |
| 关 键 词： | 结直肠癌 化学治疗 伊利替康 奥沙利铂 系统评价 Meta分析 |
| 收稿时间： | 2007-11-21 |
| 修稿时间： | 2007-12-20 |
Irinotecan versus Oxaplatin in Combination with 5-FU/LV for Advanced Colorectal Cancer:A Systematic Review |
|
| WANG ring,LUO Li-li,ZHOU Qing-hua,WU Tai-xiang.Irinotecan versus Oxaplatin in Combination with 5-FU/LV for Advanced Colorectal Cancer:A Systematic Review[J].Chinese Journal of Evidence-based Medicine,2008,8(1):36-41. | |
| Authors: | WANG ring LUO Li-li ZHOU Qing-hua WU Tai-xiang |
| Institution: | WANG Ting, LUO Li-li, ZHOU Qing-hua, WU Tai-xiang( 1. Tumor Center of West China Hospital, Sichuan University, Chengdu 610041, China; 2. The Second West China Hospital of Sichuan University, Chengdu 610041, China; 3. West China Hospital, Sichuan University, Chengdu 610041, China; Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China 4. Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, China) |
| Abstract: | Objective To compare and evaluate the effectiveness and safety of irinotecan (IRI) versus oxaplatin (OXA), in combination with 5-FU/LV for patients with advanced colorectal cancer. Methods The literature search, study selection and assessment, data collection and analysis were undertaken by two reviewers according to the Cochrane Handbook for Systematic Reviews of Interventions. Randomised controlled trials (RCTs) or quasi-RCTs comparing IRI versus OXA, in combination with 5-FU/LV in the treatment of advanced colorectal cancer were collected. Results Seven studies involving 2 107 patients were included. The OXA/5-FU/LV regimen was superior or at least equal to the IRI/5-FU/LV regimen in prolonging overall survival and time to progression. The OXA/5-FU/LV regimen showed a higher response rate and was associated with lower toxicities. Conclusion Compared with IRI, OXA is more appropriate for the treatment of advanced colorectal cancer when combined with 5-FU/LV. |
| Keywords: | Colorectal cancer Chemotherapy Irinotecan Oxaplatin Systematic review Meta analysis |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |